CA1337813C - 2-piperazinopteridines; methode de preparation; compositions pharmaceutiques a base de ces composes - Google Patents
2-piperazinopteridines; methode de preparation; compositions pharmaceutiques a base de ces composesInfo
- Publication number
- CA1337813C CA1337813C CA000552565A CA552565A CA1337813C CA 1337813 C CA1337813 C CA 1337813C CA 000552565 A CA000552565 A CA 000552565A CA 552565 A CA552565 A CA 552565A CA 1337813 C CA1337813 C CA 1337813C
- Authority
- CA
- Canada
- Prior art keywords
- acid addition
- benzylamino
- addition salt
- pteridine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims 3
- RIBWUHCWCPYSQW-UHFFFAOYSA-N 2-piperazin-1-ylpteridine Chemical class C1CNCCN1C1=NC=C(N=CC=N2)C2=N1 RIBWUHCWCPYSQW-UHFFFAOYSA-N 0.000 title description 3
- 239000002253 acid Substances 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- -1 trimethyleneimino, pyrrolidino, piperidino, hexamethyleneimino Chemical group 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 7
- 230000004614 tumor growth Effects 0.000 claims abstract description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 7
- OTDSXCQMBXZRRA-UHFFFAOYSA-N N-benzyl-6-chloro-2-piperazin-1-yl-4-piperidin-1-ylpteridin-7-amine Chemical compound C(C1=CC=CC=C1)NC1=C(N=C2C(=NC(=NC2=N1)N1CCNCC1)N1CCCCC1)Cl OTDSXCQMBXZRRA-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- GEJPLNWGEJLXJN-UHFFFAOYSA-N n-benzyl-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-ylpteridin-7-amine Chemical compound ClC1=NC2=C(N3CCCC3)N=C(N3CCNCC3)N=C2N=C1NCC1=CC=CC=C1 GEJPLNWGEJLXJN-UHFFFAOYSA-N 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000003395 phenylethylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 abstract description 10
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 206010027476 Metastases Diseases 0.000 abstract description 4
- 230000002785 anti-thrombosis Effects 0.000 abstract description 3
- 239000003146 anticoagulant agent Substances 0.000 abstract description 3
- 230000009401 metastasis Effects 0.000 abstract description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 150000003195 pteridines Chemical class 0.000 abstract description 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000002844 melting Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 10
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 229940116364 hard fat Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- FKOIJYPRGAAXKU-UHFFFAOYSA-N 2,6,7-trichloro-4-piperidin-1-ylpteridine Chemical compound C=12N=C(Cl)C(Cl)=NC2=NC(Cl)=NC=1N1CCCCC1 FKOIJYPRGAAXKU-UHFFFAOYSA-N 0.000 description 2
- KCXVCRNJUBUUHJ-UHFFFAOYSA-N 2,6-dichloro-n-phenyl-4-pyrrolidin-1-ylpteridin-7-amine Chemical compound C=12N=C(Cl)C(NC=3C=CC=CC=3)=NC2=NC(Cl)=NC=1N1CCCC1 KCXVCRNJUBUUHJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PDYZFWJEIKSQCN-UHFFFAOYSA-N N-benzyl-2,6-dichloro-4-piperidin-1-ylpteridin-7-amine Chemical compound C(C1=CC=CC=C1)NC1=C(N=C2C(=NC(=NC2=N1)Cl)N1CCCCC1)Cl PDYZFWJEIKSQCN-UHFFFAOYSA-N 0.000 description 2
- LTJLETUFCFFMEF-UHFFFAOYSA-N N-benzyl-2,6-dichloro-N-methyl-4-piperidin-1-ylpteridin-7-amine Chemical compound ClC1=NC2=NC(=C(N=C2C(=N1)N1CCCCC1)Cl)N(C)CC1=CC=CC=C1 LTJLETUFCFFMEF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- MWWFRQDJIIBUJW-UHFFFAOYSA-N n-benzyl-2,6-dichloro-4-pyrrolidin-1-ylpteridin-7-amine Chemical compound C=12N=C(Cl)C(NCC=3C=CC=CC=3)=NC2=NC(Cl)=NC=1N1CCCC1 MWWFRQDJIIBUJW-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- SYMOKCJKMFKCNO-UHFFFAOYSA-N 2,4,6,7-tetrachloropteridine Chemical compound N1=C(Cl)C(Cl)=NC2=NC(Cl)=NC(Cl)=C21 SYMOKCJKMFKCNO-UHFFFAOYSA-N 0.000 description 1
- MVBQTVSOPFOOKE-UHFFFAOYSA-N 2,6,7-trichloro-4-pyrrolidin-1-ylpteridine Chemical compound C=12N=C(Cl)C(Cl)=NC2=NC(Cl)=NC=1N1CCCC1 MVBQTVSOPFOOKE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- LJGPOIRZIBJMSB-UHFFFAOYSA-N 6-chloro-N-phenyl-2-piperazin-1-yl-6-pyrrolidin-1-yl-5H-pteridin-7-amine Chemical compound ClC1(NC=2C=NC(=NC2N=C1NC1=CC=CC=C1)N1CCNCC1)N1CCCC1 LJGPOIRZIBJMSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- VJAJMECCZAAGBJ-UHFFFAOYSA-N C1CCCN(CC1)C2=NC(=NC3=C2N=C(C(=N3)NCC4=CC=CC=C4)Cl)Cl Chemical compound C1CCCN(CC1)C2=NC(=NC3=C2N=C(C(=N3)NCC4=CC=CC=C4)Cl)Cl VJAJMECCZAAGBJ-UHFFFAOYSA-N 0.000 description 1
- WLOIGYQDWOPSDZ-UHFFFAOYSA-N C1CCCN(CC1)C2=NC(=NC3=C2N=C(C(=N3)NCC4=CC=CC=C4)Cl)N5CCNCC5 Chemical compound C1CCCN(CC1)C2=NC(=NC3=C2N=C(C(=N3)NCC4=CC=CC=C4)Cl)N5CCNCC5 WLOIGYQDWOPSDZ-UHFFFAOYSA-N 0.000 description 1
- WICDOGLMIRASKU-UHFFFAOYSA-N C1CCCN(CC1)C2=NC(=NC3=C2N=C(C(=N3)NCCC4=CC=CC=C4)Cl)Cl Chemical compound C1CCCN(CC1)C2=NC(=NC3=C2N=C(C(=N3)NCCC4=CC=CC=C4)Cl)Cl WICDOGLMIRASKU-UHFFFAOYSA-N 0.000 description 1
- CBUSOWDGJAFWOU-UHFFFAOYSA-N C=12N=C(Cl)C(Cl)=NC2=NC(Cl)=NC=1N1CCCCCC1 Chemical compound C=12N=C(Cl)C(Cl)=NC2=NC(Cl)=NC=1N1CCCCCC1 CBUSOWDGJAFWOU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- YBORXUDTFGBICE-UHFFFAOYSA-N N-benzyl-6-chloro-N-methyl-2-piperazin-1-yl-4-piperidin-1-ylpteridin-7-amine Chemical compound ClC=1N=C2C(=NC(=NC2=NC1N(C)CC1=CC=CC=C1)N1CCNCC1)N1CCCCC1 YBORXUDTFGBICE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000007957 amaurosis fugax Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 108010080511 serum sodium transport inhibitor Proteins 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3540952A DE3540952C2 (de) | 1985-11-19 | 1985-11-19 | 2-Piperazino-pteridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| CA000552565A CA1337813C (fr) | 1985-11-19 | 1987-11-24 | 2-piperazinopteridines; methode de preparation; compositions pharmaceutiques a base de ces composes |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3540952A DE3540952C2 (de) | 1985-11-19 | 1985-11-19 | 2-Piperazino-pteridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| CA000552565A CA1337813C (fr) | 1985-11-19 | 1987-11-24 | 2-piperazinopteridines; methode de preparation; compositions pharmaceutiques a base de ces composes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1337813C true CA1337813C (fr) | 1995-12-26 |
Family
ID=25671603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000552565A Expired - Fee Related CA1337813C (fr) | 1985-11-19 | 1987-11-24 | 2-piperazinopteridines; methode de preparation; compositions pharmaceutiques a base de ces composes |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA1337813C (fr) |
| DE (1) | DE3540952C2 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550472B2 (en) | 2004-11-29 | 2009-06-23 | Boehringer Ingelheim International Gmbh | Substituted pteridines for the treatment of inflammatory diseases |
| JP2009537590A (ja) * | 2006-05-24 | 2009-10-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 四員複素環で置換された置換プテリジン |
| US7648988B2 (en) | 2004-11-29 | 2010-01-19 | Boehringer Ingelheim International Gmbh | Substituted pteridines for the treatment of inflammatory diseases |
| US7718654B2 (en) | 2004-11-29 | 2010-05-18 | Boehringer Ingelheim International Gmbh | Substituted pteridines for the treatment of inflammatory diseases |
| US7750009B2 (en) * | 2004-11-29 | 2010-07-06 | Boehringer Ingelheim International Gmbh | Substituted pteridines for the treatment of inflammatory diseases |
| JP2010526764A (ja) * | 2006-05-24 | 2010-08-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換プテリジン |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10202468A1 (de) * | 2002-01-23 | 2004-09-30 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3323932A1 (de) * | 1983-07-02 | 1985-01-10 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel |
-
1985
- 1985-11-19 DE DE3540952A patent/DE3540952C2/de not_active Expired - Fee Related
-
1987
- 1987-11-24 CA CA000552565A patent/CA1337813C/fr not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550472B2 (en) | 2004-11-29 | 2009-06-23 | Boehringer Ingelheim International Gmbh | Substituted pteridines for the treatment of inflammatory diseases |
| US7648988B2 (en) | 2004-11-29 | 2010-01-19 | Boehringer Ingelheim International Gmbh | Substituted pteridines for the treatment of inflammatory diseases |
| US7718654B2 (en) | 2004-11-29 | 2010-05-18 | Boehringer Ingelheim International Gmbh | Substituted pteridines for the treatment of inflammatory diseases |
| US7750009B2 (en) * | 2004-11-29 | 2010-07-06 | Boehringer Ingelheim International Gmbh | Substituted pteridines for the treatment of inflammatory diseases |
| JP2009537590A (ja) * | 2006-05-24 | 2009-10-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 四員複素環で置換された置換プテリジン |
| JP2010526764A (ja) * | 2006-05-24 | 2010-08-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換プテリジン |
| US8877756B2 (en) | 2006-05-24 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Substituted pteridines |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3540952C2 (de) | 1997-08-14 |
| DE3540952A1 (de) | 1987-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1252783A (fr) | Pteridines, procede de preparation et utilisation comme produit intermediaire ou compose pharmaceutique | |
| CA1105941A (fr) | Traduction non-disponible | |
| CA1233179A (fr) | 2-piperazino-pteridines; methodes de preparation et compositions pharmaceutiques qui renferment ces composes | |
| JPH05500226A (ja) | 新規キサンチン化合物 | |
| JPH0641466B2 (ja) | ピラゾロトリアジン誘導体およびそれを含有するキサンチンオキシダーゼ阻害剤 | |
| KR850000216B1 (ko) | 피페라진 유도체의 제조방법 | |
| CA1337813C (fr) | 2-piperazinopteridines; methode de preparation; compositions pharmaceutiques a base de ces composes | |
| EP0198456A2 (fr) | Dérivés de la 1,7-naphtyridine et préparations médicales les contenant | |
| US4560685A (en) | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics | |
| EP0228959B1 (fr) | Composés aminostyryl, leur utilisation dans une composition leukotriène-antagoniste et procédé les utilisant pour s'opposer à l'SRS | |
| CS262690B2 (en) | Process for preparing 1-/hydroxystyryl/-5h-2,3-benzodiazepines | |
| CA1241325A (fr) | 8-alcoylthio-2-piperazino-pyrimido[5,4-d] pyrimidines; preparation et compositions pharmaceutiques qui en renferment | |
| US4021557A (en) | 11-Aminoalkyl-pyridobenzodiazepinones and salts thereof | |
| GB2092144A (en) | Novel indanyl derivaitves | |
| KR840000077B1 (ko) | 10,11-디하이드로-5H-디벤조[a, d]사이클로 헵텐-5, 10-이민의 제조방법. | |
| US4366158A (en) | 1-(8-Quinolyl)-2-pyrrolidone and its pharmaceutical compositions | |
| EP0128479B1 (fr) | Dérivés de pyrazol avec un squelette d'ergoline, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| AU626308B2 (en) | (((Cycloalkylthiazolyl)ethenyl)phenylamino)-oxoalkanoic acid derivatives | |
| NO155056B (no) | Sprengstoff. | |
| JPS5834473B2 (ja) | １，２，４↓−オキサジアゾ−ル誘導体 | |
| KR100503518B1 (ko) | 2-(4-알킬-1-피페라지닐)-벤즈알데하이드 및 -벤질리데닐화합물의 제조 방법 | |
| US4344946A (en) | 2,6-Diamino-benzo[1,2-d:5,4-d']bisthiazoles and salts thereof | |
| US4500708A (en) | Benzothiazine derivatives | |
| US3037981A (en) | Phenyltetrahydropyranylpiperazines | |
| US5422353A (en) | Tetrahydropyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |